ALLO-316 (Anti-CD70): The Next AlloCAR T™ Clinical Candidate

ALLO-316 is an anti-CD70 AlloCAR T™ candidate for renal cell carcinoma (RCC) as well as several hematological malignancies

CD70 expression¹

• RCC (80%-100%)​
• Acute myeloid leukemia (96%)​
• Diffuse large B cell lymphoma (71%), multiple myeloma (63%), chronic lymphocytic leukemia (50%)​
• Glioblastoma mutiforme (35%)​
• CD70 is also expressed on activated T cells

CD70 in RCC

• High prevalence with limited off-tumor expression​
• Good expression in metastatic disease

ALLO-316 is associated with minimal or no fratricide